All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
On January 4, 2021, it was announced that the phase Ib study arm investigating zandelisib (ME-401) in combination with zanubrutinib for the treatment of B-cell malignancies (NCT02914938) will be expanded to include disease-specific B-cell malignancy cohorts, initially follicular and mantle cell lymphoma. This was based on the recommendation by the safety review committee after completion of the safety evaluation phase.1
Secondary outcome measure: safety profile, efficacy, and pharmacokinetics.
ICML 2019 | Practice-changing abstracts
Practice-changing abstracts presented during the ICML 2019 conference.
ASH 2017 | BGB-3111 BTK inhibitor use in patients with indolent and aggressive NHL
BGB-3111 had an acceptable safety profile and was shown to have good clinical activity in both indolent and aggressive NHL subtypes, which is being further evaluated...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox